<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="90666">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01843153</url>
  </required_header>
  <id_info>
    <org_study_id>sciatic block</org_study_id>
    <nct_id>NCT01843153</nct_id>
  </id_info>
  <brief_title>Continuous Versus Intermittent Sciatic Block for Total Knee Arthroplasty</brief_title>
  <official_title>Continuous Versus Intermittent Sciatic Block Combined With a Continuous Femoral Block for Patients Undergoing Total Knee Arthroplasty: a Prospective, Randomized Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kreiskrankenhaus Dormagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kreiskrankenhaus Dormagen</source>
  <oversight_info>
    <authority>Ethics commission Germany: Aerztekammer Nordrhein, Duesseldorf</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The role of a sciatic block in addition to a femoral block remains controversial. The study
      addresses this topic by comparing a continuous block versus an injection on demand.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">April 2014</completion_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>pain score (VRS)</measure>
    <time_frame>4 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>frequency of injections into the sciatic catheter</measure>
    <time_frame>4 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Total Knee Arthroplasty</condition>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>intermittent</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>injection of ropivacaine on demand</description>
  </arm_group>
  <arm_group>
    <arm_group_label>continuous</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>continuous ropivacaine infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine</intervention_name>
    <arm_group_label>intermittent</arm_group_label>
    <arm_group_label>continuous</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients scheduled for total knee arthroplasty

        Exclusion Criteria:

          -  failure to establish femoral and sciatic block

          -  insufficient analgesic effect of the block

          -  patient declines to participate
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Stefan Soltesz, MD</last_name>
    <phone>0049 2133 66 4500</phone>
    <email>stefan.soltesz@kkh-ne.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>KKH Dormagen</name>
      <address>
        <city>Dormagen</city>
        <zip>D-51375</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Soltesz, MD</last_name>
      <phone>0049 2133 66 4500</phone>
      <email>stefan.soltesz@kkh-ne.de</email>
    </contact>
    <investigator>
      <last_name>Stefan Soltesz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 29, 2013</lastchanged_date>
  <firstreceived_date>April 25, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pain score</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
